Recommended Conferences

Genetic Engineering and Gene Therapy

Paris, France

Human Genetics and Genetic Disorders

Miami, USA

Tissue Engineering and Regenerative Medicine

Chicago, USA
Related Subjects
 

Locus-specific constitutive and cytokine-induced HLA class I gene expression

Author(s): Johnson DR

Abstract

Cytokine induction of the MHC class I genes increases the nascent molecules available for binding potentially antigenic peptides. The human H chain loci, HLA-A, -B, and -C, encode highly homologous and polymorphic mRNAs. Here, these transcripts were resolved and measured by competitive PCR of cDNA using locus-specific primers. Endothelial cells expressed many HLA-A and -B, but fewer HLA-C, transcripts. In contrast, HeLa cells expressed many HLA-A and -C, but fewer HLA-B, transcripts. The inflammatory cytokines TNF-alpha, IFN-beta, and IFN-gamma induced HLA-B strongly, but HLA-A and -C weakly in both cell types. Combined treatment with IFNs and TNF further increased HLA-A and -B, but not HLA-C transcripts. The constitutive and inducible activities of transfected promoters correlated well with mRNA levels. The weak IFN response of the HLA-A2 promoter was not due to variations in the IFN consensus sequence, the site alpha, or a 3-bp insertion between them. The HLA-Cw6 promoter was less TNF responsive due to a variant kappaB enhancer, which also reduced the IFN responses. The NF-kappaB subunit RelA strongly activated the HLA-A2 and -B7 promoters but only weakly activated the HLA-Cw6 promoter due to the variant kappaB. Cotransfecting NF-kappaB1 with RelA further increased activity of the HLA-A2 and -B7, but not HLA-Cw6, promoters. All three promoters were activated by MHC class II trans-activator, but not CREB-binding protein, whereas IFN regulatory factor-1 and -2 weakly activated the HLA-B7 and -Cw6, but not HLA-A2, promoters. These studies illustrate common and locus-specific mechanisms that may be targeted to modulate immune reactions.

Similar Articles

Psoriasis: dysregulation of innate immunity

Author(s): Bos JD, de Rie MA, Teunissen MB, Piskin G

Pathogenesis and therapy of psoriasis

Author(s): Lowes MA, Bowcock AM, Krueger JG

Interleukine-1 and interleukine- 6 in psoriasis

Author(s): Prens EP, Benne K, van DJ, Bakkus M, Brakel K, et al.

The IL-23/ Th 17 Axis in the Immunopathogenesis of Psoriasis

Author(s): Cesare DC, Meglio PD, Nestle FO

Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes

Author(s): Grossman RM, Krueger J, Yourish D, Granelli-Piperno A, Murphy DP, et al.

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

Author(s): Chaudhari U, Romano P, Mulcahy L, Dooley L, B aker D, et al.

Demonstration of novel innate immune cells in psoriasis

Author(s): Mak R, Hundhausen C, Botti E, Laggner U, Grys K, et al.

Histopathologic spectrum of psoriasis

Author(s): Murphy M, Philip K, Grant- Kels JM